UA106580C2 - Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва - Google Patents

Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва

Info

Publication number
UA106580C2
UA106580C2 UAA200907340A UAA200907340A UA106580C2 UA 106580 C2 UA106580 C2 UA 106580C2 UA A200907340 A UAA200907340 A UA A200907340A UA A200907340 A UAA200907340 A UA A200907340A UA 106580 C2 UA106580 C2 UA 106580C2
Authority
UA
Ukraine
Prior art keywords
isoglutamyl
tryptophan
pharmaceutically acceptable
timodepresinu
production
Prior art date
Application number
UAA200907340A
Other languages
English (en)
Russian (ru)
Inventor
Тім Фет Там
Блейз Н'земба
Рейс Леунг-Тоунг
Йінгсхенг Ванг
Йанквінг Жао
Лілі Иу
Original Assignee
Апотекс Технолоджис Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA106580(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Апотекс Технолоджис Інк. filed Critical Апотекс Технолоджис Інк.
Publication of UA106580C2 publication Critical patent/UA106580C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Даний належить до фармацевтично прийнятних кристалічних або аморфних солей D-ізоглутаміл-D-триптофану, а також способів їх виробництва, фармацевтичних композицій, що їх містять, та їх застосування для одержання фармацевтичних композицій для лікування різних станів та/або захворювань. Зокрема, даний винахід стосується калієвої солі D-ізоглутаміл-D-триптофану (1:1), літієвої солі D-ізоглутаміл-D-триптофану (1:1), кальцієвої солі D-ізоглутаміл-D-триптофану (2:1), магнієвої солі D-ізоглутаміл-D-триптофану (2:1).
UAA200907340A 2006-12-19 2007-12-13 Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва UA106580C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002571645A CA2571645A1 (en) 2006-12-19 2006-12-19 Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
PCT/CA2007/002235 WO2008074128A1 (en) 2006-12-19 2007-12-13 Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture

Publications (1)

Publication Number Publication Date
UA106580C2 true UA106580C2 (uk) 2014-09-25

Family

ID=39535926

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907340A UA106580C2 (uk) 2006-12-19 2007-12-13 Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва

Country Status (14)

Country Link
US (2) US8138221B2 (uk)
EP (1) EP2121729A4 (uk)
KR (1) KR20090108034A (uk)
CN (2) CN103554004A (uk)
AU (1) AU2007335212B2 (uk)
CA (2) CA2571645A1 (uk)
CL (1) CL2007003680A1 (uk)
MX (1) MX2009006673A (uk)
PE (2) PE20121642A1 (uk)
RU (1) RU2536685C2 (uk)
TW (1) TWI406872B (uk)
UA (1) UA106580C2 (uk)
UY (1) UY30798A1 (uk)
WO (1) WO2008074128A1 (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579119C (en) 2007-02-16 2013-03-05 Apotex Technologies Inc. Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
RU2634258C1 (ru) * 2016-11-08 2017-10-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Наполнитель для капсульного ингалятора
RU2703991C1 (ru) * 2019-02-12 2019-10-23 Акционерное общество "Медико-биологический научно-производственный комплекс "Цитомед" (АО "МБНПК "Цитомед") Способ получения мононатриевой соли изоглутамил-триптофана

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3238118A1 (de) 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing Verfahren zur herstellung von komplexverbindungen aus aminodicarbonsaeuren, zweiwertigen metallionen und halogenidionen
AU566747B2 (en) 1984-01-10 1987-10-29 Mitsui Chemicals, Inc. Method of separating l-tryptophan
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
RU2107691C1 (ru) * 1995-03-02 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US6103699A (en) * 1996-06-07 2000-08-15 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
DE19540788A1 (de) * 1995-11-02 1997-05-07 Degussa Verwendung von wässrigen L-Tryptophan- und/oder L-Threonin-Salzlösungen
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
IL120923A0 (en) * 1997-05-27 1997-09-30 Amylum Nv A combined process for the production of lysine and its salts and of a further weak acid and a salt thereof
EP2046778B1 (en) * 2006-08-04 2013-12-04 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
CA2569204A1 (en) * 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan

Also Published As

Publication number Publication date
PE20081402A1 (es) 2008-11-16
CN101611050A (zh) 2009-12-23
CL2007003680A1 (es) 2008-03-14
MX2009006673A (es) 2009-11-02
RU2536685C2 (ru) 2014-12-27
EP2121729A1 (en) 2009-11-25
CA2571645A1 (en) 2008-06-19
CN101611050B (zh) 2013-10-30
AU2007335212B2 (en) 2013-09-05
US20130072692A1 (en) 2013-03-21
CA2673421A1 (en) 2008-06-26
RU2009127795A (ru) 2011-01-27
KR20090108034A (ko) 2009-10-14
PE20121642A1 (es) 2012-12-16
CN103554004A (zh) 2014-02-05
TWI406872B (zh) 2013-09-01
US20100056803A1 (en) 2010-03-04
UY30798A1 (es) 2008-07-03
WO2008074128A1 (en) 2008-06-26
US8735602B2 (en) 2014-05-27
AU2007335212A1 (en) 2008-06-26
EP2121729A4 (en) 2013-07-31
US8138221B2 (en) 2012-03-20
TW200833708A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2008055814A3 (en) Process for the preparation of (s)-4-fluoromethyl-dihydro-furan-2-one
MX2009005413A (es) Formas cristalinas del acido zoledronico.
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
MY174776A (en) Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
MY177111A (en) Substituted amide derivatives and methods of use
MY167135A (en) Fused heterocyclic derivatives and methods of use
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
PL1751093T3 (pl) Podstawione pochodne kwasu cykloheksylooctowego
UA108058C2 (uk) Кристалічний d-ізоглутаміл-d-триптофан і моноамонійна сіль d-ізоглутаміл-d-триптофану
WO2009047775A3 (en) Polymorphs of esomeprazole salts
WO2010107807A3 (en) Compounds for treating inflammation and pain
TW200628474A (en) Organic compounds
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
PL1745010T3 (pl) Podstawione pochodne cykloheksylo-1,4-diaminy
UA106580C2 (uk) Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
WO2010079045A3 (en) Crystalline salt forms of flibanserine
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
ATE466010T1 (de) Verfahren zur herstellung von candesartan
WO2007083243A3 (en) An improved process for the preparation of risedronate sodium hemi-pentahydrate
WO2013043744A3 (en) Tricyclic compounds useful as neurogenic and neuroprotective agents